Viking Therapeutics stock trades at EUR 25.68 on Thursday

Company: Viking Therapeutics
ISIN: US92686J1060
Ticker: VKTX
Trading venue: Lang & Schwarz
Quote: EUR 25.68 at 13:31 CET on Thursday, November 12, 2026

Published on 11/12/2026 at 13:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Viking Therapeutics stock remains tied to a clinical-stage pipeline in metabolic and endocrine disorders. VK2735 is advancing through Phase 3 obesity studies.

What investors are watching next

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders.
Its VK2735 program includes Phase 3 studies of subcutaneous and oral treatments for obesity.

VKTX, US92686J1060, Illustration mit AI erstellt.

Viking Therapeutics stock traded at EUR 25.68 on Lang & Schwarz at 13:31 CET on Thursday, November 12, 2026.

Pipeline focus remains on metabolic disorders

Viking Therapeutics describes itself as a clinical-stage biopharmaceutical company focused on novel therapies for metabolic and endocrine disorders, according to its investor-relations overview.

The company is evaluating VK2735 in obesity. Its development program includes Phase 3 studies of a subcutaneous formulation and separate Phase 3 studies of an oral formulation. Viking also lists VK2809, DACRA candidates and VK0214 among its development programs.